European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 147, Issue 1 , Pages 101-105 , November 2009

Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease

  • Jean-Guillaume Ferron

      Affiliations

    • Department of Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Catherine Uzan

      Affiliations

    • Department of Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Annie Rey

      Affiliations

    • Department of Biostatistics, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Sebastien Gouy

      Affiliations

    • Department of Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Patricia Pautier

      Affiliations

    • Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Catherine Lhommé

      Affiliations

    • Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Pierre Duvillard

      Affiliations

    • Department of Pathology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Philippe Morice

      Affiliations

    • Department of Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 42 11 44 39; fax: +33 1 42 11 52 13.

Received 31 March 2009 ,Revised 23 July 2009 ,Accepted 25 July 2009.

References 

  1. Griffiths TC, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979;63:235–240
  2. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259
  3. Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47:203–209
  4. Van der Burg ME, Van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332:629–634
  5. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;1030:1070–1076
  6. Le T, Shahriari P, Hopkins L, Faught W, Fung Kee Fung M. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer. 2006;16:986–990
  7. Le T, Williams K, Senterman M, et al. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol. 2007;106:160–163
  8. Le T, Williams K, Senterman M, Hopkins L, Faught W, Fung-Kee-Fung M. Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol. 2007;14:2649–2653
  9. Sassen S, Schmalfeldt B, Avril N, et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol. 2007;38:926–934
  10. Morice P, Brehier-Ollive D, Rey A, et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-nonexposed study. Ann Oncol. 2003;14:74–77
  11. Morice P, Dubernard G, Rey A, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg. 2003;197:955–963
  12. Lhommé C, Joly F, Walker JL, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008;26:2674–2682
  13. Cure H, Battista C, Guastalla JP, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc ASCO. 2004;22(450s):A5006
  14. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4:212–236
  15. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304–9311
  16. Rajan R, Esteva FJ, Symmans WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response. Clin Breast Cancer. 2004;5:235–238
  17. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–327
  18. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–4422
  19. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–1530
  20. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma clinicopathologic correlations. Cancer. 1994;73:2680–2686
  21. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684–692
  22. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol. 2006;103:559–564
  23. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77–85
  24. Tiersten A, Liu P, Smith H, et al. Phase II evaluation of neoadjuvant chemotherapy and interval debulking surgery followed by intraperitoneal chemotherapy in women with stage III and IV epithelial, fallopian tube, or primary peritoneal cancer: a Southwest Oncology Group study. Gynecol Oncol. 2008;108(Suppl. 1):S3

PII: S0301-2115(09)00485-0

doi: 10.1016/j.ejogrb.2009.07.016

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 147, Issue 1 , Pages 101-105 , November 2009

Article Tools

* Image Usage & Resolution